Combination of Peptide YY3–36with GLP-17–36 amideCauses an Increase in First-Phase Insulin Secretion after IV Glucose

Autor: Ian F. Godsland, Ali Alsafi, Rachel C. Troke, Victoria Salem, Mandy Donaldson, Mohammad A. Ghatei, Kevin C.R. Baynes, James Minnion, Benjamin C. T. Field, Stephen R. Bloom, Tricia Tan, Akila De Silva, Shivani Misra
Přispěvatelé: Medical Research Council (MRC)
Rok vydání: 2014
Předmět:
Blood Glucose
Male
FOOD-INTAKE
Endocrinology
Diabetes and Metabolism
medicine.medical_treatment
Clinical Biochemistry
GASTRIC BYPASS
Hot Topics in Translational Endocrinology
Biochemistry
0302 clinical medicine
Endocrinology
APPETITE
Glucagon-Like Peptide 1
Homeostasis
Insulin
Glucose homeostasis
0303 health sciences
Glucose tolerance test
medicine.diagnostic_test
digestive
oral
and skin physiology
Middle Aged
Glucagon-like peptide-1
NEUROPEPTIDE-Y
Female
SENSITIVITY
Life Sciences & Biomedicine
hormones
hormone substitutes
and hormone antagonists
Adult
endocrine system
medicine.medical_specialty
030209 endocrinology & metabolism
Context (language use)
Biology
CELL FUNCTION
Endocrinology & Metabolism
Young Adult
03 medical and health sciences
Insulin resistance
Internal medicine
Diabetes mellitus
medicine
Endocrine Research
Humans
Peptide YY
Obesity
BARIATRIC SURGERY
030304 developmental biology
RELEASE
Science & Technology
PYY3-36
MORTALITY
Biochemistry (medical)
1103 Clinical Sciences
Glucose Tolerance Test
Overweight
medicine.disease
Peptide Fragments
Glucose
1114 Paediatrics and Reproductive Medicine
Insulin Resistance
Zdroj: E2324
E2317
The Journal of Clinical Endocrinology and Metabolism
ISSN: 1945-7197
0021-972X
DOI: 10.1210/jc.2014-2143
Popis: Context: The combination of peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) has been proposed as a potential treatment for diabetes and obesity. However, the combined effects of these hormones, PYY3–36 and GLP-17–36 amide, on glucose homeostasis are unknown. Objective: This study sought to investigate the acute effects of PYY3–36 and GLP-17–36 amide, individually and in combination, on insulin secretion and sensitivity. Setting and Design: Using a frequently sampled iv glucose tolerance test (FSIVGTT) and minimal modeling, this study measured the effects of PYY3–36 alone, GLP-17–36 amide alone, and a combination of PYY3–36 and GLP-17–36 amide on acute insulin response to glucose (AIRg) and insulin sensitivity index (SI) in 14 overweight human volunteers, studied in a clinical research facility. Results: PYY3–36 alone caused a small but nonsignificant increase in AIRg. GLP-17–36 amide alone and the combination of PYY3–36 and GLP-17–36 amide did increase AIRg significantly. No significant differences in SI were observed with any intervention. Conclusions: PYY3–36 lacks any significant acute effects on first-phase insulin secretion or SI when tested using an FSIVGTT. Both GLP-17–36 amide alone and the combination of PYY3–36 and GLP-17–36 amide increase first-phase insulin secretion. There does not seem to be any additive or synergistic effect between PYY3–36 and GLP-17–36 amide on first-phase insulin secretion. Neither hormone alone nor the combination had any significant effects on SI.
Databáze: OpenAIRE
Externí odkaz: